SCHEMBL98756

SCHEMBL98756

CCN(CC)CCN(CC)C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13884285 0.94
SCHEMBL99335 0.92 MEN1 (0.34) MEN1POLBKMT2A
SCHEMBL24965367 0.88
SCHEMBL15471302 0.87
SCHEMBL27069740 0.84 MEN1 (0.31) MEN1POLBKMT2A
SCHEMBL27069754 0.82 MEN1 (0.30) MEN1POLBKMT2A
SCHEMBL99336 0.82 CYP1A2 (0.31)
SCHEMBL15471304 0.80 CYP1A2 (0.36)
SCHEMBL27069805 0.80
SCHEMBL13893518 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10960053-B2 PEGylated recombinant human growth hormone compounds ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2021-03-30 US disclosed
US-20200261544-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2020-08-20 US disclosed
US-20190192634-A1 PEGylated Recombinant Human Growth Hormone Compounds ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2019-06-27 US disclosed
US-20180185452-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2018-07-05 US disclosed
US-9919033-B2 Dry growth hormone composition transiently linked to a polymer carrier ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2018-03-20 US disclosed
US-9802941-B2 Compounds and methods for inhibiting histone demethylases GILEAD SCIENCES, INC. (US) 2017-10-31 US disclosed
US-20170056477-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2017-03-02 US disclosed
US-20170056477-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2017-03-02 US disclosed
US-20170008888-A1 HETEROCYCLIC COMPOUNDS ACTIVX BIOSCIENCES, INC. 2017-01-12 US disclosed
US-20160206702-A1 PEGylated Recombinant Human Growth Hormone Compounds ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-07-21 US disclosed
US-9272048-B2 PEGylated recombinant human growth hormone compounds ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-03-01 US disclosed
US-9272048-B2 PEGylated recombinant human growth hormone compounds ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-03-01 US disclosed
US-9139609-B2 C-4″ position substituted macrolide derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-09-22 US disclosed
US-20140046043-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE MEIJI SEIKA PHARMA CO., LTD. (JP) 2014-02-13 US disclosed
US-20120058084-A1 Interferon Alpha Carrier Prodrugs ASCENDIS PHARMA AS (DK) 2012-03-08 US disclosed
US-20120058084-A1 Interferon Alpha Carrier Prodrugs ASCENDIS PHARMA AS (DK) 2012-03-08 US disclosed
US-20110112021-A1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS ASCENDIS PHARMA AS (DK) 2011-05-12 US disclosed
US-20110112021-A1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS ASCENDIS PHARMA AS (DK) 2011-05-12 US disclosed
US-20070293511-A1 Crf Receptor Antagonists and Methods SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION 2007-12-20 US disclosed
US-20030153754-A1 Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE 2003-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293511-A1 Crf Receptor Antagonists and Methods CRHR1, CRHR2, CRH MEN1 1548/4885POLB 4702/4885KMT2A 2996/4885
US-20200261544-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier GHRHR, GHSR, GCG MEN1 402/4885POLB 3675/4885KMT2A 1703/4885
US-20170008888-A1 HETEROCYCLIC COMPOUNDS BET1, EP300, RBBP5 MEN1 1184/4885POLB 1717/4885KMT2A 1805/4885
US-10960053-B2 PEGylated recombinant human growth hormone compounds GHRHR, GHITM, GHSR MEN1 672/4885POLB 2582/4885KMT2A 2937/4885
US-20170056477-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier GHRHR, GHSR, GCG MEN1 402/4885POLB 3675/4885KMT2A 1703/4885
US-20190192634-A1 PEGylated Recombinant Human Growth Hormone Compounds GHRHR, GHITM, GHSR MEN1 672/4885POLB 2582/4885KMT2A 2937/4885
US-20110112021-A1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS GHRHR, GHITM, GHSR MEN1 672/4885POLB 2582/4885KMT2A 2937/4885
US-20160206702-A1 PEGylated Recombinant Human Growth Hormone Compounds GHRHR, GHITM, GHSR MEN1 672/4885POLB 2582/4885KMT2A 2937/4885
US-20140046043-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE MRPL21, MRPS34, MRPL37 MEN1 1302/4885POLB 1523/4885KMT2A 3170/4885
US-20180185452-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier GHRHR, GHSR, GCG MEN1 402/4885POLB 3675/4885KMT2A 1703/4885
US-20030153754-A1 Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands GABRB1, GABRB3, GABRB2 MEN1 4750/4885POLB 2052/4885KMT2A 1954/4885
US-20120058084-A1 Interferon Alpha Carrier Prodrugs IFNG, IFNAR1, IRF3 MEN1 4083/4885POLB 233/4885KMT2A 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.